Woodline Partners’s Bright Minds Biosciences DRUG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.28M Hold
45,668
– – 0.01% 865
2026
Q2
$3.21M Hold
45,668
– – 0.01% 780
2026
Q1
$3.33M Buy
+45,668
New +$3.68M 0.01% 732

Other funds holding DRUG

Woodline Partners's DRUG Position: Q3 2026 in Review

Woodline Partners held its Bright Minds Biosciences (DRUG) position steady in Q3 2026 at 45,668 shares worth $2.28M. The position accounts for 0.01% of the portfolio, ranked #865.

Woodline Partners first reported a position in DRUG in Q1 2026 and has held it in 3 quarters since. The position peaked at $3.33M in Q1 2026. 110 funds tracked by Wall St. Rank hold DRUG as of Q3 2026.

  • Woodline Partners held 45,668 shares of Bright Minds Biosciences worth $2.28M as of Q3 2026.
  • Woodline Partners left its Bright Minds Biosciences share count unchanged in Q3 2026.
  • Bright Minds Biosciences made up 0.01% of Woodline Partners's portfolio in Q3 2026, its #865 holding.
  • Woodline Partners first reported a position in Bright Minds Biosciences in Q1 2026 and has held it in 3 quarters since.
  • Woodline Partners's Bright Minds Biosciences position peaked at $3.33M in Q1 2026.
  • 110 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q3 2026.

Based on Woodline Partners's 13F filing for Q3 2026, filed 16 Nov 2026.